Resistomap (Biotechnology, Health Care) — Funding, Investors & Signals 2026

Resistomap

Monitoring today, impacting tomorrow. - Combat antimicrobial resistance using advanced environmental DNA technology.

Founded 2018 Finland

Finland 16 employees Seed Total: $2.00M Biotechnology, Health Care

Resistomap, established in 2018 and headquartered in Finland, is a biotechnology startup with a focused mission to combat the proliferation of antibiotic resistance in the environment. The company's expertise lies in microbial antibiotic resistance, molecular genetics, and data science, enabling it to facilitate swift and comprehensive detection and quantification of antibiotic resistance genes in environmental samples, using cutting-edge gene profiling technology. Their goal is to predict and prevent outbreaks of antibiotic-resistant bacteria. Catering primarily to research groups studying environmental samples, such as surface water, wastewater, soil, stool, and tissue samples, Resistomap is also working on digitalizing antibiotic resistance monitoring in wastewater. This innovation is poised to serve as an early warning system, adept at identifying impending outbreaks of resistant bacteria. The company offers end-to-end services, including consultation on sample collections, DNA extraction, quantification of antibiotic resistance genes using the SmartChip Real-Time PCR system, comprehensive data analysis, and reporting. Recently, Resistomap secured a €2.00M Seed Round investment on 15 November 2023. The investment was led by Ananda Impact Ventures and Gaingels, illustrating investor confidence in the company's potential to make a significant impact within the biotechnology and healthcare industries.

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	••••••	1		15 Nov 2023
Seed Round	••••••	2		15 Nov 2023

Funding Stage

Amount

Investors

Lead Investors

Date

Grant

••••••

15 Nov 2023

Seed Round

••••••

15 Nov 2023

FAQ About Resistomap

Monitoring today, impacting tomorrow. - Combat antimicrobial resistance using advanced environmental DNA technology.

Resistomap was founded in 2018.

Resistomap is headquartered in Finland.

Resistomap operates in the following industries: Biotechnology, Health Care.

Resistomap has approximately 16 employees.

Resistomap has completed 2 funding rounds, raising a total of $2.00M. The latest funding stage is Seed.

Top alternatives and competitors to Resistomap include OpGen, Inc., LimmaTech Biologics AG, illumr, Madam Therapeutics, AUROBAC THERAPEUTICS. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Resistomap and OpGen, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Resistomap

General Information

Track Resistomap

Discover More

About Resistomap

Funding Rounds & Investors (2)

Latest News

Resistomap Alternatives & Competitors

FAQ About Resistomap

Don't just browse. Track.